GeoVax Announces License Agreement With NIH to Support Continued Advancements in Vaccine Development
November 30 2020 - 9:00AM
via NewMediaWire -- GeoVax Labs,
Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”),
a biotechnology company developing human immunotherapies and
vaccines against infectious diseases and cancer, today announced
the signing of a Patent and Biological Materials License Agreement
(the “License Agreement”) with the National Institute of Allergy
and Infectious Diseases (NIAID), part of the National Institutes of
Health (NIH), in support of GeoVax’s non-clinical development of
vaccines against numerous pathogens.
The License Agreement provides GeoVax with access
to certain materials and patent rights owned by agencies of the
Department of Health and Human Services (HHS) for use in
combination with the Company’s proprietary technology for the
creation of preventive and/or therapeutic vaccines against
Ebola-Zaire, Ebola-Sudan, Lassa virus, Marburg virus, Zika virus
and malaria. The agreement also extends to the Company’s research
and development efforts in certain oncology areas. The agreement
provides GeoVax with nonexclusive rights for the nonclinical
development and manufacturing of its vaccine and immunotherapy
candidates using HHS patents and materials. Financial terms
of the License Agreement were not disclosed.
David Dodd, GeoVax President and CEO, commented,
“This research license agreement is important to GeoVax’s
ongoing vaccine and cancer immunotherapy developments as it
provides us with the rights for continued use of the HHS patents
and materials in our research and development programs. If we later
decide to commercialize vaccine candidates that are subject to this
license, we will negotiate appropriate commercialization licenses
at that time, similar to that recently completed related to our
COVID-19 vaccine program.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing human vaccines against infectious
diseases and cancer using a novel patented Modified Vaccinia
Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On
this platform, MVA, a large virus capable of carrying several
vaccine antigens, expresses proteins that assemble into VLP
immunogens within (in vivo) the person receiving the vaccine. The
production of VLPs in the person being vaccinated can mimic virus
production in a natural infection, stimulating both the humoral and
cellular arms of the immune system to recognize, prevent, and
control the target infection. The MVA-VLP derived vaccines can
elicit durable immune responses in the host similar to a
live-attenuated virus, while providing the safety characteristics
of a replication-defective vector.
GeoVax’s current development programs are focused
on preventive vaccines against COVID-19, HIV, Zika Virus,
hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and
malaria, as well as therapeutic vaccines against multiple cancers.
The Company has designed a preventive HIV vaccine candidate to
fight against the subtype of HIV prevalent in the commercial
markets of the Americas, Western Europe, Japan, and Australia;
human clinical trials for this program are managed by the HIV
Vaccine Trials Network (HVTN) with the support of the National
Institutes of Health (NIH). GeoVax’s HIV vaccine candidate is also
part of two separate collaborative efforts to apply its innovative
gene therapy approach toward a functional cure for HIV.
Forward-Looking Statements
This release contains forward-looking statements
regarding GeoVax’s business plans and financial result. This
release and the related conference call discuss forward-looking
statements regarding GeoVax’s ability to implement its business
plan, expected revenues and future success. The words “believe,”
“may,” “estimate,” “continue,” “anticipate,” “intend,” “should,”
“plan,” “could,” “target,” “potential,” “is likely,” “will,”
“expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
can develop and manufacture its vaccines with the desired
characteristics in a timely manner, GeoVax’s vaccines will be safe
for human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s vaccines will receive regulatory
approvals necessary to be licensed and marketed, GeoVax raises
required capital to complete vaccine development, there is
development of competitive products that may be more effective or
easier to use than GeoVax’s products, GeoVax will be able to enter
into favorable manufacturing and distribution agreements, the
impact of the COVID-19 pandemic continues, and other factors, over
which GeoVax has no control.
Further information on our risk factors is
contained in our most recent Quarterly Report on Form 10-Q
that we have filed with the SEC. Any forward-looking statement
made by us herein speaks only as of the date on which it is made.
Factors or events that could cause our actual results to differ may
emerge from time to time, and it is not possible for us to predict
all of them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
GeoVax Labs,
Inc.678-384-7220investor@geovax.com
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Apr 2023 to Apr 2024